Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lake, Jordan E., McComsey, Grace A., Hulgan, Todd, Wanke, Christine A., Mangili, Alexandra, Walmsley, Sharon L., Currier, Judith S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567084/
https://www.ncbi.nlm.nih.gov/pubmed/26380350
http://dx.doi.org/10.1093/ofid/ofv059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567084/
https://www.ncbi.nlm.nih.gov/pubmed/26380350
http://dx.doi.org/10.1093/ofid/ofv059

Ejemplares similares